Presentation
Leveraging an Integrated AI and New Approach Methodologies (NAMs) Safety Strategy to Understand Multi-Organ Safety Risk in Drug Discovery
Date: July 3, 2025
Time: 16:30 - 18:00
Speaker: Paul Walker Ph.D. (VP Head of Toxicology and Innovation Efficiency)
High drug failure rates within drug development remains a significant concern. To predict human safety liabilities integration of new approach methodologies (NAMs) into early drug discovery has gained significant momentum. The use of NAMs allows for greater understanding of drug mechanisms and prediction of toxicity potential earlier in the discovery process. By leveraging human-relevant high throughput in vitro assays, such as 3D organ systems, and transcriptomic profiling, chemical series can be assessed and triaged based on their toxicity profile. We are going to present a study that illustrates the benefits of using NAMs to de-risk compounds in early drug discovery.
